Additionally, it is difficult to determine whether patients who benefit from GLP-1 receptor agonist therapy are benefiting from treatment of PCOS-related manifestations, such as obesity and insulin resistance, rather than treating the root cause of PCOS. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.